MUC16 and endometrial cancer: A validation cohort confirmed PAAP’s effectiveness, detecting endometrial cancer in 11 out of 17 advanced-stage samples and 13 out of 23 early-stage samples, whereas CA125 detected only 5 out of 17 advanced-stage samples and 4 out of 23 early-stage samples.